Regeneron Pharmaceuticals, Inc. $REGN Stock Purchased by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 28,232 shares of the biopharmaceutical company’s stock after buying an additional 2,832 shares during the quarter. Factory Mutual Insurance Co.’s holdings in Regeneron Pharmaceuticals were worth $21,407,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. State Street Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after buying an additional 170,210 shares during the period. Bank of America Corp DE increased its position in shares of Regeneron Pharmaceuticals by 8.5% during the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock worth $805,023,000 after acquiring an additional 101,469 shares in the last quarter. Amundi increased its position in shares of Regeneron Pharmaceuticals by 0.4% during the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after acquiring an additional 3,742 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $473,872,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. This trade represents a 8.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,493 shares of company stock worth $6,866,845 over the last ninety days. 6.97% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research reports. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Tuesday, July 7th. Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Monday. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a report on Monday. Raymond James Financial lifted their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Weiss Ratings raised Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $898.97.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported third-quarter revenue of $5.12 billion, up 36.3% year over year and ahead of estimates, while earnings of $20.07 per share also topped consensus. Analysts pointed to strength in commercial products and progress in the pipeline as signs of underlying business health. REGN Q3 deep dive: pipeline progress and core brands drive outperformance
• Positive Sentiment: Following the results, multiple firms raised their price targets; some maintained Buy or Overweight ratings, and forecasts cited in coverage reached as high as $1,175. These revisions reflect improved expectations after the earnings beat. Analysts raise forecasts after upbeat Q3 results
• Neutral Sentiment: Director Kathryn Guarini sold 400 shares under a pre-arranged Rule 10b5-1 trading plan. The planned nature of the sale may reduce its significance as a signal about the company’s outlook. SEC filing
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, with a 0.4% indicated yield. Management also scheduled appearances at upcoming healthcare investor conferences; neither announcement provides a major near-term earnings catalyst. Investor conference presentations
• Negative Sentiment: Despite raising targets, several firms—including RBC, Morgan Stanley, Bernstein and Wells Fargo—kept neutral-style ratings and set targets below the recent share price, signaling valuation caution after the stock’s rally. RBC comments on Regeneron’s Q3 results

Regeneron Pharmaceuticals Stock Up 1.3%

Regeneron Pharmaceuticals stock opened at $973.36 on Wednesday. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $798.74 and a 200 day simple moving average of $740.16. The company has a market cap of $100.22 billion, a P/E ratio of 20.13, a price-to-earnings-growth ratio of 1.51 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $975.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s revenue was up 36.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $11.83 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is currently 8.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.